Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Narrative (Details)

v3.23.3
Commitments and Contingencies - Narrative (Details)
$ in Thousands
 3 Months Ended 9 Months Ended
Jul. 19, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Mar. 31, 2023
site
Nov. 15, 2022
May 01, 2021
period
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Renewal options | period               4
Renewal period (in years)             1 year 1 year
Agreement term (in days)               90 days
License agreement term (in days) 10 days              
Number Of Sites | site           12    
General and administrative expense   $ 8,245 $ 7,512 $ 26,480 $ 21,643      
License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
General and administrative expense   $ 400   $ 1,100        
License Agreement                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Upfront license fee $ 50              
License or royalty net revenue percentage 3.00%              
Royalty expense $ 250              
License Agreement | Phase 3                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Additional payment of fee 900              
License Agreement | New Drug Application                
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                
Additional payment of fee $ 1,000